MA-CENTERITY
22.10.2020 15:02:08 CEST | Business Wire | Press release
Centerity Systems, Inc. , the leading AIOps Platform with advanced performance analytics and integrated security, today announced its recognition as a Top Value Leader in the latest “EMA Radar Report: AIOps – A Guide for Investing in Innovation .”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005664/en/
EMA evaluated 17 AIOps vendors on (i) Business Impact and IT-to-Business Alignment, (ii) Incident, Performance, and Availability Management, and (iii) Change Impact and Capacity Optimization use cases to guide organizations with their AIOps platform selection. Centerity’s AIOps Platform is designated as a market leader in all of the use cases EMA evaluated. Centerity is a front-runner in delivering exceptional value in both the Business Impact and IT-to-Business Alignment and Incident, Performance, and Availability Management use cases, due to its technical strength, impact on business outcomes, and deployment cost efficiency. In addition, Centerity was honored by EMA with a special award for advanced integrated security functionality.
The Centerity AIOps Platform improves performance and reliability of business and operational processes, employing an approach that continuously measures the overall health of key technology services by providing real-time, consolidated business analytics. SLA executive dashboards expose business and security risks, identify performance anomalies, and provide fault isolation across applications, operating systems, infrastructure and cloud assets. It does this by automating topology and dependency maps of all IT assets, incorporating each asset into business and operational service views. Its AI-driven anomaly detection and multi-tenancy supports multi-user, multi-vendor, and multi-location management, which is ideal for managed service providers, cloud service providers, and enterprises.
“Centerity is a unique innovator in the AIOps arena,” said Dennis Drogseth, EMA vice president. “Centerity stands out for its advancing use of AI/ML in a variety of contexts, including ‘CyberOps,’ as well as its distinctive strengths in discovery across domains, data assimilation, and unifying views and dashboards. These strengths, along with the platform’s fast time to value and limited administrative overhead all help to make Centerity both a versatile and progressive choice for AIOps adopters.” According to EMA’s evaluation, the Centerity AIOps platform is differentiated among its competitors by:
-
Delivering many of the benefits of larger and more costly AIOps suites with reduced administrative overhead and more modest software costs.
-
Bringing the full seven-layer stack together with an eye toward IT service performance and business outcomes and priorities across cloud, hybrid, and legacy environments.
- Integrating artificial intelligence and machine learning capabilities to support security and risk management needs – such as cybersecurity compliance, endpoint detection and response (EDR), supply chain security, and automated prevention of attacks on network hardware.
According to EMA, the message for IT organizations looking to pursue a forward path in AIOps adoption is overall a strongly positive one. The benefits achieved are growing in diversity and value. AIOps can and should be transformative in enabling more effective decision-making, data sharing, and analytics-driven automation. The recommendation from EMA remains that buyers should consider their own realities, then begin a search for the AIOps platform that most fits their requirements.
“In the digital age, AIOps, security and risk management must be observed and correlated through a single platform,” said Roi Keren, CEO of Centerity Systems. “That’s not only what we see our customers need and want, it’s what Centerity does best. EMA’s positioning of Centerity and award for integrated security acknowledges the convergence of AIOps and security. It’s more critical than ever for enterprise executives – whether you’re a CIO, CISO, CEO, or board member -- to make strategic, risk-based business decisions with one platform, one dashboard; in essence, a single source of truth.”
AIOps Deployments and the Real Word: Bringing Operations and Security Together
Enterprises can see how others are deploying AIOps to address a variety of use cases by viewing a live EMA-hosted webcast titled “AIOps Deployments and the Real World: Bringing Operations and Security Together ,” which will be held on Tuesday, November 10th at 1:00 pm EST. You can register for the webcast at https://info.enterprisemanagement.com/aiops-deployments-in-the-real-world-webinar-centerity .
About Centerity
Centerity’s Cyber-AIOps Platform with advanced Integrated Security delivers Dynamic Business Service Views of the full technology stack to the executives responsible for technology-driven business services, ensuring the performance, availability and security of critical processes. Centerity displays real-time, consolidated business analytics for complex on-prem, cloud, and hybrid technology environments generating SLA Executive Dashboards that identify performance anomalies and isolate faults across applications, operating systems, infrastructure and cloud assets. Learn more at centerity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005664/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
